{"analyses":[{"ciLowerLimit":"0.747","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.212","groupDescription":"The 2-sided P-value was based on stratified log-rank test (stratification factors: prior Trastuzumab (concurrent or sequential), nodal status (\\<=3 or \\>=4) and ER/PgR status (positive or negative). The hazard ratio and corresponding 95% CI from the stratified cox proportional hazard model were also presented.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6914","paramType":"Hazard Ratio (HR)","paramValue":"0.952","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.13","upperLimit":"99.85","value":"99.64"},{"groupId":"OG001","lowerLimit":"98.86","upperLimit":"99.71","value":"99.43"}]}],"title":"1 Year Kaplan-Meier Estimate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.62","upperLimit":"97.57","value":"96.74"},{"groupId":"OG001","lowerLimit":"95.30","upperLimit":"97.31","value":"96.44"}]}],"title":"3 Year Kaplan-Meier Estimate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.65","upperLimit":"95.25","value":"94.09"},{"groupId":"OG001","lowerLimit":"91.77","upperLimit":"94.49","value":"93.26"}]}],"title":"5 Year Kaplan-Meier Estimate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.66","upperLimit":"92.79","value":"91.36"},{"groupId":"OG001","lowerLimit":"89.62","upperLimit":"92.70","value":"91.29"}]}],"title":"7 Year Kaplan-Meier Estimate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.97","upperLimit":"90.84","value":"89.06"},{"groupId":"OG001","lowerLimit":"88.58","upperLimit":"90.43","value":"88.65"}]}],"title":"9 Year Kaplan-Meier Estimate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1420"},{"groupId":"OG001","value":"1420"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause, censored at the last date known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.","id":"OG000","title":"Neratinib"},{"description":"Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year.Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Intent to treat (ITT) population included all participants who were randomized regardless of whether they received any study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization until death due to any cause (up to 119 Months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}